- February 25, 2022
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
– Acquisition of next-generation Kv7 channel activators for target...
Read more » - February 3, 2022
Third Pole Therapeutics Closes $25M Financing - eNOfit™ Wearable Device Now Ready for Clinical Trials
– eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device...
Read more »
Recent News
Third Pole Theraputics

In 1998, three American scientists were awarded the Nobel Prize for their identification of Nitric Oxide